Form 4: Natera Co-Founder Jonathan Sheena Sells Shares

Natera Director and Co-Founder Jonathan Sheena sold 3,544 shares of common stock in late April 2026, primarily through a pre-arranged trading plan.

Summary

• Jonathan Sheena, a Director and Co-Founder of Natera, Inc., sold a total of 3,544 shares of common stock over two days in April 2026.
• On April 27, 2026, 473 shares were sold at prices between $203.75 and $204.39 to satisfy tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
• On April 29, 2026, 3,071 shares were sold at weighted average prices ranging from $196.21 to $196.98 per share.
• The sales on April 29 were executed under a Rule 10b5-1 trading plan adopted on December 11, 2024.
• Following these transactions, Sheena directly owns 255,711 shares of Natera common stock.
• Sheena also maintains indirect ownership of 40,564 shares held in two separate trusts for beneficiaries.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it is an insider sale, the small size relative to total holdings and the use of a 10b5-1 plan mitigate concerns of opportunistic trading.

Positives

• The reporting person retains a substantial direct ownership stake of 255,711 shares, worth approximately $50 million at current prices.
• The majority of the sales were conducted via a Rule 10b5-1 plan, which provides an affirmative defense against insider trading by scheduling trades in advance.
• A portion of the sales was non-discretionary, specifically intended to cover mandatory tax obligations from RSU vestings.

Negatives

• The sales occurred at prices lower than the peaks seen earlier in the week, with the April 29 sales executed at roughly $196 compared to $204 on April 27.
• Insider selling, regardless of the reason, can sometimes be interpreted by the market as a lack of near-term catalysts or a signal that the stock is fully valued.

Risks

• Market volatility may impact the execution price of future scheduled sales under the existing 10b5-1 plan.
• Potential negative investor sentiment if high-level insiders continue to divest significant portions of their holdings.

Future Outlook

The reporting person continues to hold a significant equity position in the company, though the existence of a 10b5-1 plan suggests that additional scheduled sales may occur in the future to provide liquidity or diversification.

Management Comments

• The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of Restricted Stock Units.
• The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2024.

Industry Context

StockSavvy.ai notes that in the high-growth diagnostics and biotech sector, it is standard practice for founders and long-tenured directors to utilize 10b5-1 plans for orderly divestment and tax management without disrupting market liquidity.

Comparison to Industry Standards

• The use of 10b5-1 plans is a standard governance practice among executives at peer companies such as Exact Sciences (EXAS) and Guardant Health (GH).
• The volume of the sale represents less than 1.5% of the insider's total direct and indirect holdings, which is considered a minor liquidation compared to industry averages for founders.

Corporate Governance

Stakeholder Impact

• Shareholders may see minor downward pressure on the stock price during the execution of these trades, though the volume is relatively low.
• The reporting person remains a significant stakeholder, aligning his interests with long-term shareholders.

Next Steps

• Monitor for subsequent Form 4 filings to determine if the 10b5-1 plan includes additional monthly or quarterly tranches.

Key Dates

Recommendation

The insider activity is routine and does not signal a fundamental change in the company's prospects. The co-founder remains heavily invested in the company's success.

Keywords

Natera, NTRA, Insider Selling, Form 4, Jonathan Sheena, Rule 10b5-1, Restricted Stock Units, Biotechnology, Genetic Testing